The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Benefits and Costs of Using HPV Testing to Screen for Cervical Cancer
Abstract
CONTEXT: Despite quality assurance standards, Papanicolaou (Pap) test characteristics remain less than optimal. OBJECTIVE: To compare the societal costs and benefits of human papillomavirus (HPV) testing, Pap testing, and their combination to screen for cervical cancer. DESIGN, SETTING, AND POPULATION: A simulation model of neoplasia natural history was used to estimate the societal costs and quality-adjusted life expectancy associated with 18 different general population screening strategies: Pap plus HPV testing, Pap testing alone, and HPV testing alone every 2 or 3 years among hypothetical longitudinal cohorts of US women beginning at age 20 years and continuing to 65 years, 75 years, or death. MAIN OUTCOME MEASURE: Discounted costs per quality-adjusted life-year (QALY) saved of each screening strategy. RESULTS: Maximal savings in lives were achieved by screening every 2 years until death with combined HPV and Pap testing at an incremental cost of $76 183 per QALY compared with Pap testing alone every 2 years. Stopping biennial screening with HPV and Pap testing at age 75 years captures 97.8% of the benefits of lifetime screening at a cost of $70 347 per QALY. Combined biennial HPV and Pap testing to age 65 years captures 86.6% of the benefits achievable by continuing to screen until age 75 years. Human papillomavirus screening alone was equally effective as Pap testing alone at any given screening interval or age of screening cessation but was more costly and therefore was dominated. In sensitivity analyses, HPV testing would be more effective and less costly than Pap testing at a cost threshold of $5 for an HPV test. CONCLUSIONS: Screening with HPV plus Pap tests every 2 years appears to save additional years of life at reasonable costs compared with Pap testing alone. Applying age limits to screening is a viable option to maintain benefits while reducing costs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1994) · doi:10.1201/9780429246593 · Cited by 40,500
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective
Bosch, F. X., Manos, M. M., Munoz, N., Sherman, M., Jansen, A. M., Peto, J., Schiffman, M. H., Moreno, V., Kurman, R., Shan, K. V., et al. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.11.796 · Cited by 3,370
Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer
Rose, P. G., Bundy, B. N., Watkins, E. B., Thigpen, J. T., Deppe, G., Maiman, M. A., Clarke-Pearson, D. L., & Insalaco, S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904153401502 · Cited by 2,658
Morris, M., Eifel, P. J., Lu, J., Grigsby, P. W., Levenback, C., Stevens, R. E., Rotman, M., Gershenson, D. M., & Mutch, D. G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904153401501 · Cited by 2,299
Guide to Clinical Preventive Services
Wesley Allen, T. (1991) · The Journal of the American Osteopathic Association · doi:10.1515/jom-1991-900515 · Cited by 2,129
Keys, H. M., Bundy, B. N., Stehman, F. B., Muderspach, L. I., Chafe, W. E., Suggs, C. L., Walker, J. L., & Gersell, D. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904153401503 · Cited by 1,923
Moses, L. E., Shapiro, D., & Littenberg, B. (1993) · Statistics in Medicine · doi:10.1002/sim.4780121403 · Cited by 1,405
Schiffman, M. H., Bauer, H. M., Hoover, R. N., Glass, A. G., Cadell, D. M., Rush, B. B., Scott, D. R., Sherman, M. E., Kurman, R. J., Wacholder, S., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.12.958 · Cited by 1,210
Epidemiology of Genital Human Papillomavirus Infection
Koutsky, P. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00177-0 · Cited by 1,107
Cited by
Human papillomavirus and cervical cancer
Burd, E. M. (2003) · Clinical Microbiology Reviews · doi:10.1128/cmr.16.1.1-17.2003 · Cited by 2,420
American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer
Saslow, D., Runowicz, C. D., Solomon, D., Moscicki, A.-B., Smith, R. A., Eyre, H. J., & Cohen, C. (2002) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.52.6.342 · Cited by 927
Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine
Goldie, S. J., Kohli, M., Grima, D., Weinstein, M. C., Wright, T. C., Bosch, F. X., & Franco, E. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh104 · Cited by 539
Cytology versus HPV testing for cervical cancer screening in the general population
Koliopoulos, G., Nyaga, V. N., Santesso, N., Bryant, A., Martin-Hirsch, P. P., Mustafa, R. A., Schünemann, H., Paraskevaidis, E., & Arbyn, M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008587.pub2 · Cited by 494
Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs
Kulasingam, S. L. (2003) · JAMA · doi:10.1001/jama.290.6.781 · Cited by 337
Metadata
- Authors
- Mandelblatt, J. S.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2002-05-08
- Volume
- 287
- Issue
- 18
- Pages
- 2372
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1992161500
- Cited by
- 308
- References
- 101
- FWCI
- 21.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Benefits and Costs of Using HPV Testing to Screen for Cervical Cancer. https://app.cochat.ai/papers/10.1001/jama.287.18.2372
- The paper
- Mandelblatt, J. S. (2002). Benefits and Costs of Using HPV Testing to Screen for Cervical Cancer. JAMA. https://doi.org/10.1001/jama.287.18.2372
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.